AstraZeneca top loser on FTSE 100 after heart disease drug fails late-stage trial
09/07/2026 08:26
BUZZ-AstraZeneca top loser on FTSE 100 after heart disease drug fails late-stage trial ** Shares of AstraZeneca AZN.L slump as much as 9.6% to 12,874p; on track for their worst day since 2017
** AZN is top loser on FTSE 100 .FTSE index, which is down 0.4%
** Co says its nerve disease drug Wainua, made in partnership with Ionis IONS.O, failed to meet main goal of reducing cardiovascular deaths & recurring heart problems in a late-stage trial
** AZN down 6% YTD
(Reporting by Nithyashree R B in Bengaluru)
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains